Evidence map›Paper›PMID 37740149›Full record

ArticleDermatology and therapy2023

Burden of Herpes Zoster Among Patients with Psoriasis in the United States.

David Singer, Philippe Thompson-Leduc, Siyu Ma, Deepshekhar Gupta, Wendy Y Cheng, Selvam R Sendhil, Manasvi Sundar, Ella Hagopian, Nikita Stempniewicz, Mei Sheng Duh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

David SingerGSK, US Health Outcomes and Epidemiology, Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA19104, USA.ORCID http://orcid.org/0000-0001-8008-8003
Philippe Thompson-LeducAnalysis Group, Inc., Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-9047-3941
Siyu MaGSK, US Health Outcomes and Epidemiology, Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA19104, USA.ORCID http://orcid.org/0000-0001-7269-2884
Deepshekhar GuptaAnalysis Group, Inc., Menlo Park, CA, USA.ORCID http://orcid.org/0000-0002-3695-3546
Wendy Y ChengAnalysis Group, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0002-8281-2496
Selvam R SendhilAnalysis Group, Inc., Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8010-4296
Manasvi SundarAnalysis Group, Inc., Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-5858-8685
Ella HagopianAnalysis Group, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0003-0506-7004
Nikita StempniewiczGSK, US Health Outcomes and Epidemiology, Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA19104, USA. nikita.x.stempniewicz@gsk.com.ORCID http://orcid.org/0000-0002-0877-4460
Mei Sheng DuhAnalysis Group, Inc., Boston, MA, USA.ORCID http://orcid.org/0000-0001-5035-6687
Sara PostonGSK, US Health Outcomes and Epidemiology, Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA19104, USA.ORCID http://orcid.org/0000-0003-4735-057X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with psoriasis (PsO) are at increased risk of herpes zoster (HZ), but recent data on the incidence of HZ among patients with PsO and the impact of HZ on healthcare resource use (HRU) and costs for patients with PsO have not been described.

methodsThis retrospective, longitudinal, cohort study estimated HZ incidence in cohorts of adults with vs without PsO (PsO + vs PsO-) and HRU and costs among those with PsO, with vs without HZ (PsO + /HZ + vs PsO + /HZ-) using Optum's de-identified Clinformatics Data Mart Database during 2015-2020. Patients with psoriatic arthritis were excluded from all four cohorts. Comparisons between cohorts used generalized linear models to adjust outcomes based on various baseline characteristics.

resultsThe incidence rate of HZ was significantly higher in the PsO + (n = 144,115) vs PsO- (n = 23,837,237) cohorts at 11.35 vs 7.67 per 1000 patient-years; adjusted incidence rate ratio (aIRR): 1.21, 95% confidence interval (CI): 1.16-1.25. HRU (outpatient, emergency department, and inpatient) was significantly higher in the PsO + /HZ + (n = 1859) vs PsO + /HZ- (n = 78,664) cohorts during 1 month and 3 months after HZ diagnosis (e.g., outpatient visits during month: 2.83 vs 1.30 per patient; aIRR: 1.96; 95% CI 1.86-2.06). Mean all-cause costs were also significantly higher in the PsO + /HZ + vs PsO + /HZ- cohort during both month ($5020 vs $2715 per patient; adjusted cost difference: $1390; 95% CI $842-$1964) and 3 months ($12,305 vs $8256; adjusted cost difference: $1422; 95% CI $280-$2889) after HZ diagnosis.

conclusionThese findings show the increased incidence of HZ among patients with PsO and the clinical and economic burdens of HZ in this population. Considering the high prevalence of PsO, insights into the impact of HZ in these patients provide valuable evidence to inform clinical decision-making.

Indexed as

BurdenClaims databaseCostsHealthcare resource useHerpes zosterIncidencePsoriasisUnited States

Identifiers

PMID37740149
PMCPMC10613173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.